1.
|
The appointment of Dr Anne Beal was made by the Board on the
recommendation of the Nominations & Corporate Governance
Committee.
|
|
2.
|
The Board has determined that Dr Beal will be an independent
Non-Executive Director on appointment in accordance with the UK
Corporate Governance Code.
|
|
3.
|
Dr Beal will receive the standard basic fee for a Non-Executive
Director of £95,000 per annum. She will receive a further
payment of £40,000 per annum when she succeeds Ms Elsenhans as
Chair of the Corporate Responsibility Committee.
Dr Beal will be required to invest at least 25% of her fees in GSK
shares that should be held until her retirement from the
Board.
|
|
4.
|
Membership of other Committees will be determined in due
course.
|
|
5.
|
Dr Beal does not have a service contract. She has a letter of
appointment which may be viewed by contacting the Company Secretary
at the Company's registered office.
|
|
6.
|
There are no additional details to disclose in respect of Dr Beal's
appointment under Listing Rule 9.6.13R.
|
|
7.
|
From 6 May 2021 the Board of GSK will comprise:
|
|
|
Sir Jonathan Symonds
Emma
Walmsley
Iain
Mackay
Dr Hal Barron
Vindi Banga
Charles Bancroft
Dr Anne Beal
Dr Vivienne
Cox
Lynn
Elsenhans
Dr Jesse Goodman
Dr Laurie Glimcher
Urs
Rohner
|
Non-Executive Chairman
Chief Executive Officer
Chief Financial Officer
Chief Scientific Officer and President, R&D
Senior Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
Independent Non-Executive Director
|
|
As previously announced, Charles Bancroft has succeeded Judy Lewent
as Chair of the Audit & Risk Committee following approval of
GSK's 2020 Annual Report. Judy will not stand for re-election to
the Board at GSK's Annual General Meeting on 5 May
2021.
Lynn Elsenhans will stand for re-election at the AGM and remain on
the Board for a further year to facilitate a smooth handover to Dr
Beal.
|
GSK enquiries:
|
|
|
|
Media enquiries:
|
Simon Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
Madeleine Breckon
|
+44 (0) 7880 040 329
|
(London)
|
|
Kristen Neese
|
+1 804 217 8147
|
(Philadelphia)
|
|
|
|
|
Analyst/Investor enquiries:
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Sonya Ghobrial
|
+44 (0) 7392 784784
|
(Consumer)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: April
06, 2021
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|